Why Guardant Complete Conveniently unlock the most dynamic view of cancer with circulating tumor DNA (ctDNA).1
Here's how Guardant Complete is completely transforming the way you see what's next, now:
Identifies minimal residual disease (MRD) and recurrence to guide critical adjuvant therapy decisions as soon as 2-3 weeks post-surgery.2
Enables >50% faster time-to-treatment vs tissue testing alone when you initiate liquid and tissue comprehensive genomic profiling (CGP) at the same time.3
Predicts treatment response
8 weeks before a routine radiographic assessment in patients with advanced-stage progression.4
Rely on Guardant Complete as your all-in-one testing partner across the cancer continuum.
Get end-to-end support for all your liquid and tissue testing needs:
Easy order forms:
Submit one form for early-stage MRD detection and another form for advanced-stage response monitoring and CGP testing.
Convenient Guardant portal:
Keep track of testing results in a single portal that you can easily review with patients.
Customized support services:
Find a consistent set of resources for troubleshooting and personalized service for the clinical staff.
Backed by >80 clinical outcomes studies and >350 peer-reviewed publications.
With reliable results and seamless support, Guardant Complete offers more options to meet your precision oncology testing needs.